FGFR3 and bladder transitional cell carcinoma: On the other hand, Wang et al. examined whether BLCA with FGFR3 mutations shows a distinct clinical response to CPIs based on the data from two clinical trials: the IMVigor 210 trial [17] exploring the PD-L1 inhibitor atezolizumab in 274 patients with metastatic UC and the CheckMate 275 [19] exploring the PD-1 inhibitor nivolumab in 139 patients with metastatic UC [20].